Brain natriuretic peptide (BNP) testing in the emergency department

Journal of Emergency Medicine

Volumn 31, Issue 2, 2006, Pages 201-210

  Mayo, Douglas D ^a   Colletti, James E ^b   Kuo, Dick C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

BNP; brain natriuretic peptide; congestive heart failure; diagnosis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SPIRONOLACTONE;

ACUTE CORONARY SYNDROME; ARTICLE; CONGESTIVE HEART FAILURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DYSPNEA; EMERGENCY WARD; HUMAN; IMMUNOFLUORESCENCE TEST; KIDNEY FAILURE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE;

BIOLOGICAL MARKERS; DYSPNEA; EMERGENCIES; HEART FAILURE, CONGESTIVE; HUMANS; KIDNEY FAILURE, ACUTE; NATRIURETIC PEPTIDE, BRAIN; POINT-OF-CARE SYSTEMS; SENSITIVITY AND SPECIFICITY; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33748044833     PISSN: 07364679     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jemermed.2005.08.022     Document Type: Article

References (79)

1. Kisch B. Electron microscopy of the atrium of the heart. I guinea pig. Exp Med Surg 14 (1956) 99-112
2. Kangawa K., Fukuda A., Minamino N., et al. Purification and complete amino sequence of beta-rat atrial natriuretic polypeptide (beta-rANP) at 5000 daltons. Biochem Biophys Res Commun 119 (1984) 933-940
3. Sudah T., Kangawa K., Minamino N., et al. A new natriuretic peptide in porcine brain. Nature 332 (1988) 78-81
4. Hosada K., Nakao K., Mukoyama M., et al. Expression of brain natriuretic peptide gene in human heart. Hypertension 17 (1991) 1152-1155
5. Yasue H., Yoshimura M., Sumida H., et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90 (1994) 195-203
6. Vesley D.L., Douglas M.A., Dietz J.R., et al. Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans. Circulation 90 (1994) 1129-1140
7. Mattingly M.T., Brandt R.R., Henblein D.M., et al. Presence of C-type natriuretic peptide in human kidney and urine. Kidney Int 46 (1994) 744-747
8. Nakagawa O., Ogawa Y., Itoh H., et al. Rapid transcriptional activation and early mRNA turnover of BNP in cardiocyte hypertrophy. evidence for BNP as an "emergency" cardiac hormone against ventricular overload. J Clin Invest 96 (1995) 1280-1287
9. Dickstein K. Natriuretic peptides in detection of heart failure. Lancet 35 (1998) 3-4
10. Hall C. Essential biochemistry and physiology of (NT-pro) BNP. Eur J Heart Fail 6 (2004) 257-260
11. Sonnenberg J.L., Sakane Y., Jeng A.Y., et al. Identification of protease 3.4.24.11 as a major atrial natriuretic factor degrading enzyme in rat kidney. Peptides 9 (1998) 173-180
12. Schrier R.W., and Abraham W.T. Hormones and hemodynamics in heart failure. N Engl J Med 341 (1999) 577-585
13. Kelly R., and Struthers A.D. Are natriuretic peptides clinically useful as markers of heart failure?. Ann Clin Biochem 38 (2001) 94-102
14. Heart Disease and Stroke Statistics - 2004 Update. Dallas, TX: American Heart Association.
15. Struthers A.D. Heart failure. the diagnosis of heart failure. Heart 84 (2000) 334-338
16. Davie A.P., Francis C.M., Caruara L., et al. Assessing diagnosis in heart failure. which features are any use?. Q J Med 90 (1997) 335-339
17. Dao Q., Krishnaswamy P., Kazahegra R., et al. Utility of b-type naturietic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 37 (2001) 379-385
18. Adams K.F. New epidemiologic perspectives concerning mild heart failure. Am J Med 110 (2001) 65-135
19. Maisel A., Krishnaswamny P., Nowak R., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347 (2002) 161-167
20. McCullough P.A., Nowak R.M., McCord J., et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure. analysis from breathing not properly (BNP) multinational study. Circulation 106 (2002) 416-422
21. Davis M., Espiner E., Richards G., et al. Plasma brain natriuretic peptide in assessment of acute dyspnea. Lancet 343 (1994) 440-444
22. Morrison L.K., Harrison A., Krishnaswamy P., et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 39 (2002) 202-209
23. Schwam E. B-type natriuretic peptide for diagnosis of heart failure in emergency department patients. a critical appraisal. Acad Emerg Med 11 (2004) 686-691
24. Logeart D., Saudubray C., Beyne P., et al. Comparative value of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea. J Am Coll Cardiol 40 (2002) 1794-1800
25. Villacorta H., Duarte A., Duarte N.M., et al. The role of B-type natriuretic peptide in the diagnosis of congestive heart failure in patients presenting to an emergency department with dyspnea. Arq Bras Cardiol 79 (2002) 564-572
26. Lainchbury J.G., Campbell E., Frampton C.M., et al. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 42 (2003) 728-735
27. McCullough P.A., and Sandberg K.R. Sorting out the evidence on natriuretic peptides. Rev Cardiovasc Med 4 Suppl 4 (2003) S13-S19
28. Nagaya N., Nishikimi T., Okano Y., et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 31 (1998) 202-208
29. Maeda K., Tsutamoto T., Wada A., et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 135 (1998) 825-832
30. Kazanegra R., Cheng V., Garcia A., et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure. a pilot study. J Card Fail 7 (2001) 21-29
31. Cheng V., Kazangara R., Garcia A., et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure. a pilot study. J Am Coll Cardiol 37 (2001) 386-391
32. Kuster G., Tanner H., Printzen G., et al. B-type natriuretic peptide for diagnosis and treatment of congestive heart failure. Swiss Med Wkly 133 (2003) 623-628
33. Bettencourt P., Frioes F., Azevedo A., et al. Prognostic information provided by serial measurements of brain natriuretic peptide in heart failure. Int J Cardiol 93 (2004) 45-48
34. Maisel A., Hollander J., Guss D., et al. Primary results of the rapid emergency department heart failure outpatient trial (REDHOT)). J Am Coll Cardiol 44 (2004) 1328-1333
35. Harrison A., Morrison L., Krishnaswamy P., et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 39 (2002) 131-138
36. Cohn J.N., Johnson G.R., Shabetas R., et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. the V-HeFT VA cooperative studies group. Circulation 87 (1993) VI5-VI16
37. White H.D., Norris R.M., Brown M.A., et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76 (1987) 44-51
38. Tsutamoto T., Wada A., Maeda K., et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure. prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96 (1997) 509-516
39. Koglin J., Pehlivanli S., Schwaiblmair M., et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 38 (2001) 1934-1941
40. Richards A.M., Doughty R., Nicholls M.G., et al., Australia-New Zealand Heart Failure Group. Neurohormonal prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Circulation 99 (1999) 786-792
41. Anand I., Fisher L.D., Change Y.T., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure trial (Val-HeFT). Circulation 107 (2003) 1278-1283
42. Maeda K., Tsutamoto T., Wada A., et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 36 (2000) 1587-1593
43. Harrison A., Morrison L.K., Krishnaswamy P., et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 39 (2002) 131-138
44. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 (1987) 1429-1435
45. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
46. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II). a randomized trial. Lancet 353 (1999) 9-13
47. The RESOLVD Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy; the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation 101 (2000) 378-384
48. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heary failure. randomized evaluation of strategies for left ventricular dysfunction pilot study. N Engl J Med 341 (1999) 709-717
49. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Eng J Med 344 (2001) 1651-1658
50. Motwani J.G., McAlpine H., Kennedy N., et al. Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet 341 (1993) 1109-1113
51. Yasuda S., Goto Y., Sumida H., et al. Angiotensin-converting enzyme inhibition restores hepatocyte growth factor production in patients with congestive heart failure. Hypertension 33 (1999) 1374-1378
52. Yoshimura M., Yasue H., Tanaka H., et al. Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an andiotensin-converting enzyme inhibitor, in patients with congestive heart failure. Br Heart J 72 (1994) 528-533
53. van Veldhuisen D.J., Genth-Zotz S., Brouwer J., et al. High-versus low-dose ACE inhibition in chronic heart failure. a double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol 32 (1998) 1811-1818
54. Brunner-La Rocca H.P., Weilenmann D., Kiowski W., et al. Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure. Am Heart J 138 (1999) 654-662
55. Tsutamoto T., Wada A., Maeda K., et al. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol 35 (2000) 714-721
56. McKelvie R.S., Yusuf S., Pericak D., et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study: the RESOLVD Pilot Study Investigators. Circulation 100 (1999) 1056-1064
57. Latini R., Masson S., Anand I., et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure. the Valsartan Heart Failure Trial (Val-HeFT). Circulation 106 (2002) 2454-2458
58. Murdoch D.R., McDonagh T.A., Byrne J., et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration. randomized comparison of the neurodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 138 (1999) 1126-1132
59. Sanderson J.E., Chan W.W., Hung Y.T., et al. Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure. a double blind, randomized comparison of metoprolol and a third generation vasodilating beta blocker. Br Heart J 74 (1995) 502-507
60. Hara Y., Hamada M., Shigematsy Y., et al. Effect of beta-blocker on left ventricular function and natriuretic peptides in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitor. Jpn Circ J 64 (2000) 365-369
61. Fujimura M., Yasamura Y., Ishida Y., et al. Improvement in left ventricular function in response to carvedilol is accompanied by attenuation of Neurohormonal activation in patients with dilated cardiomyopathy. J Card Fail 6 (2000) 3-10
62. Kawai K., Hata K., Takaoka H., et al. Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy. a potential of hormone-guided treatment. Am Heart J 141 (2001) 925-932
63. Troughton R.W., Frampton C.M., Yandle T.G., et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000) 1126-1130
64. Vesley D.L. Natriuretic peptides and acute renal failure. Am J Physiol Renal Physiol 285 (2003) F167-F177
65. Mallamaci F. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int 59 (2001) 1559-1566
66. Osajima A. Comparison of plasma levels of mature adrenomedulin and natriuretic peptide as markers of cardiac function in hemodialysis patients with coronary artery disease. Nephron 92 (2002) 832-839
67. Cataliotti A. Circulating natriuretic peptide concentrations in patients with end-stage renal disease. role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc 76 (2001) 1111-1119
68. McCullough P.A. B-type natriuretic peptide and renal function in the diagnosis of heart failure. an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 41 (2003) 571-579
69. Goto T. Increased circulating levels of natriuretic peptides predict future cardiac event in patients with chronic hemodialysis. Nephron 92 (2002) 610-615
70. Naganuma T. The prognostic role of brain natriuretic peptides in hemodialysis patients. Am J Nephrol 22 (2002) 437-444
71. Osajima A. Clinical significance of natriuretic peptides and cyclic GMP in hemodialysis patients with coronary artery disease. Am J Nephrol 21 (2001) 112-119
72. Tulevski I.I., Hirsch A., Sanson B.J., et al. Increased brain natriuretic peptide as a marder for right ventricular dysfunction in acute pulmonary embolism. Thromb Haemost 86 (2001) 1193-1196
73. Nagaya N., Nishikimi T., Uematsu M., et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102 (2000) 865-870
74. Nagaya N., Sasaki N., Ando M., et al. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. Chest 123 (2003) 338-343
75. Suzuki T., Hayashi D., Yamazaki T., et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 136 (1998) 362-363
76. Hohl C.M., Mitelman B.Y., Wyer P., et al. Should emergency physicians use B-type natriuretic peptide testing in patients with unexplained dyspnea. Can J Emerg Med 5 (2003) 162-165
77. McCullough P.A., Hollander J.E., Nowak R.M., et al. Uncovering heart failure in patients with a history of pulmonary disease. rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med 10 (2003) 198-204
78. Wu A.H., Harrison A., and Maisel A.S. Reduced readmission rate for alternating diagnoses of heart failure and pulmonary disease after implementation of B-type natriuretic peptide testing. Eur J Heart Fail 6 (2004) 309-312
79. Mueller C., Scholer A., Laule-Kilian K., et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 350 (2004) 647-654